Hims & Hers Health, Inc. HIMS Analyst Ratings

16 ratings from Wall Street analysts · latest analyst action Feb 10, 2026

Analyst Ratings
Buy Consensus target withheld — no analyst update in over 90 days showing 16 ratings
Latest analyst action Feb 10, 2026
HIMS
Initiated
2026-01-12
Evercore ISI
RatingIn-line
From—
Target$33
From—
Initiated
2025-12-09
Barclays
RatingOverweight
From—
Target$48
From—
Reiterated
2025-06-04
Needham
RatingBuy
From—
Target$65
From$61
Downgrade
2025-04-29
TD Cowen
RatingHold
FromBuy
Target$30
From—
Downgrade
2025-02-18
Morgan Stanley
RatingEqual-Weight
FromOverweight
Target$60
From$42
Downgrade
2025-01-10
Citigroup
RatingSell
FromNeutral
Target$25
From$24
Initiated
2025-01-07
BTIG Research
RatingBuy
From—
Target$35
From—
Initiated
2024-12-17
Morgan Stanley
RatingOverweight
From—
Target$42
From—
Initiated
2024-08-22
Needham
RatingBuy
From—
Target$24
From—
Downgrade
2024-05-22
Citigroup
RatingNeutral
FromBuy
Target$20
From$16
Downgrade
2024-04-16
Jefferies
RatingHold
FromBuy
Target$15
From$17
Initiated
2024-04-10
Canaccord Genuity
RatingBuy
From—
Target$20
From—
Upgrade
2024-02-28
Imperial Capital
RatingOutperform
FromIn-line
Target$16
From—
Initiated
2024-02-26
Leerink Partners
RatingMarket Perform
From—
Target$10
From—
Initiated
2023-12-07
Imperial Capital
RatingIn-line
From—
Target$9
From—
Initiated
2023-07-28
TD Cowen
RatingOutperform
From—
Target$11
From—